Skip to content

News

First large study of IP strategies now available online

One of the very first comprehensive empirical studies of IP strategies in large corporations is now available here. It was originally published as chapter 7 in Ove Granstrand’s widely recognized book from 1999: The Economics and Management of Intellectual Property. The study is based on the concept of a strategy ladder, enabling the integration of IP strategies laterally across main IPR types and vertically with technology and business strategies. After a survey of a number of advantages and disadvantages of patenting from a corporate perspective, the chapter reviews generic patent strategies and counterstrategies, litigation strategies, secrecy strategies and counterstrategies and other IPR strategies, that can be used jointly in multi-protection. The empirical survey and case studies mainly focus on IP strategies in large Japanese corporations and how they responded to US corporate patent and litigation strategies.

Check out the study to gain further insights into IP strategies that are still relevant today, not the least in light of the evolving IP strategy game between US and China.

Berkeley summer program

Our researcher Marcus Holgersson is currently hosting the 2019 Berkeley summer program at UC Berkeley. The program admits 35 of our high-performing students in Industrial Engineering and Management at Chalmers, and includes studies at UC Berkeley, visits to tech firms in Silicon Valley, and case projects with startups in the area. The program started a couple of weeks ago, and has already included visits to organizations such as Tesla Motors, Volvo Group, Stanford University, Nordic Innovation House, and ETC Labs, an accelerator for blockchain technologies and cryptocurrencies. Much more is to follow! A visit to the baseball game between Oakland A’s and Tampa Bay Rays made a relaxing break after an intense first week. The program runs until mid-August.

The students in front of Sproul Hall, UC Berkeley. Program manager Marcus Holgersson on the far right. Martin Luther King Jr. held a famous anti-war speech on these very same stairs on May 17, 1967.
Oakland A’s had no chance against Tampa Bay Rays, despite the unusual support from Swedish students

IP pharma challenges in 2019

In connection to the publication of a new issue of the Stockholm Intellectual Property Law Review, where our researcher Marcus Holgersson serves on the board of directors, a seminar on IP pharma challenges in 2019 was held in Stockholm on June 4, 2019. The seminar covered several important topics, including the use of and uncertainty related to doctrines of equivalents, the opportunities and risks with CRISPR-Cas9 gene editing technologies, and branding and trademarking pharmaceuticals. Much more can be read about these topics in the latest issue of Stockholm Intellectual Property Law Review, available here.

The seminar was followed by a dinner, celebrating the recent graduates of the IP Law master program of Stockholm University. We wish the students best of luck with their future careers in the IP Law field.


Thomas Hedner from IMIT giving a thought-provoking talk on the opportunities and risks with CRISPR-Cas9
Kristina Björnerstedt from Skriptor Zigila talking about the structured process of naming your business, product, or pharmaceutical

John Hornby from Lambert Hornby Ltd talking about the doctrine of equivalents from a UK perspective

Bengt Domeij from Uppsala University giving a Swedish perspective, also on the doctrine of equivalents
Students celebrated by parts of the Swedish IP community

Recent talks delivered by Ove Granstrand

Professor Ove Granstrand has during the spring held several fascinating talks on the theme: ”Do patents and innovations contribute to growth and welfare?”

Following up on his first Leverhulme Trust Lecture held in December on the Nobel Laureates in Economics’ work on Technology, IP, Innovation and Growth, Granstrand focused his second talk on presenting some of his own research from his recently published book within the area. The talk covered topics such as the innovation spiral and the links between its variables, the critiques of and motives behind the patent system and some global challenges with the needs for institutional innovations to manage them. Astra’s medical drug Losec and the role of patenting and evergreening strategy in its success was discussed, among other case studies within the medical and telecommunications industries. 

Another talk was delivered by Professor Granstrand at Freie Universität in Berlin on May 28. 

The invitation to Professor Granstrand’s second Leverhulme Trust Lecture, delivered at the Department of Engineering at University of Cambridge on May 2.